CL2020002284A1 - Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc) - Google Patents

Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc)

Info

Publication number
CL2020002284A1
CL2020002284A1 CL2020002284A CL2020002284A CL2020002284A1 CL 2020002284 A1 CL2020002284 A1 CL 2020002284A1 CL 2020002284 A CL2020002284 A CL 2020002284A CL 2020002284 A CL2020002284 A CL 2020002284A CL 2020002284 A1 CL2020002284 A1 CL 2020002284A1
Authority
CL
Chile
Prior art keywords
crystalline forms
sgc
stimulant
guanylyl cyclase
soluble guanylyl
Prior art date
Application number
CL2020002284A
Other languages
English (en)
Inventor
Thomas Storz
Kwame W Nti-Addae
Leena Kumari Prasad
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65818696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020002284(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of CL2020002284A1 publication Critical patent/CL2020002284A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación se relaciona con formas cristalinas de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1H-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina, que son útiles como estimuladores de guanilato ciclasa soluble (sGC). La presente divulgación también provee composiciones farmacéuticamente aceptables que comprenden las formas cristalinas y métodos para usar dichas composiciones en el tratamiento de diversas afecciones.
CL2020002284A 2018-03-07 2020-09-03 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc) CL2020002284A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862639846P 2018-03-07 2018-03-07

Publications (1)

Publication Number Publication Date
CL2020002284A1 true CL2020002284A1 (es) 2020-11-27

Family

ID=65818696

Family Applications (5)

Application Number Title Priority Date Filing Date
CL2020002284A CL2020002284A1 (es) 2018-03-07 2020-09-03 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc)
CL2021000301A CL2021000301A1 (es) 2018-03-07 2021-02-04 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). solicitud divisional de sol. 2284-2020.
CL2021003530A CL2021003530A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 1 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina solicitud divisional de solicitud 2284-2020.
CL2021003531A CL2021003531A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 2 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina. solicitud divisional de solicitud 2284-2020
CL2021003536A CL2021003536A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 3 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina . solicitud divisional de solicitud 2284-2020

Family Applications After (4)

Application Number Title Priority Date Filing Date
CL2021000301A CL2021000301A1 (es) 2018-03-07 2021-02-04 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). solicitud divisional de sol. 2284-2020.
CL2021003530A CL2021003530A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 1 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina solicitud divisional de solicitud 2284-2020.
CL2021003531A CL2021003531A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 2 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina. solicitud divisional de solicitud 2284-2020
CL2021003536A CL2021003536A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 3 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina . solicitud divisional de solicitud 2284-2020

Country Status (21)

Country Link
US (3) US11466015B2 (es)
EP (1) EP3762389B1 (es)
JP (1) JP7423539B2 (es)
KR (1) KR102782810B1 (es)
CN (1) CN111836812A (es)
AU (1) AU2019231724B2 (es)
BR (1) BR112020018212A2 (es)
CA (1) CA3092683A1 (es)
CL (5) CL2020002284A1 (es)
CO (1) CO2020012493A2 (es)
CR (1) CR20200458A (es)
EA (1) EA202092109A1 (es)
ES (1) ES2980256T3 (es)
IL (1) IL276853B1 (es)
MA (1) MA54638A (es)
MX (5) MX2023004857A (es)
PE (1) PE20210124A1 (es)
PH (1) PH12020551394A1 (es)
SG (1) SG11202008641WA (es)
TW (1) TWI823903B (es)
WO (1) WO2019173551A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019231724B2 (en) 2018-03-07 2024-06-27 Tisento Therapeutics Inc. Crystalline forms of an sGC stimulator
KR20250141845A (ko) * 2018-07-11 2025-09-29 티센토 쎄라퓨틱스 인크. 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도
US20230130739A1 (en) * 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
CN118221651A (zh) * 2022-12-21 2024-06-21 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途
AU2023412228A1 (en) * 2022-12-21 2025-07-03 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
CZ302691B6 (cs) 1998-07-08 2011-09-07 Sanofi - Aventis Deutschland GmbH N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
BRPI0816382A2 (pt) 2007-09-06 2015-02-24 Merck Sharp & Dohme Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças
WO2009094242A1 (en) 2008-01-24 2009-07-30 Merck & Co., Inc. Angiotensin ii receptor antagonists
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
KR20110133034A (ko) 2009-02-26 2011-12-09 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 시클라제 활성화제
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
KR20140019004A (ko) 2010-05-27 2014-02-13 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 시클라제 활성화제
EP2588465B1 (en) 2010-06-30 2017-01-25 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP2632551B1 (en) 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN107266433A (zh) 2010-11-09 2017-10-20 铁木医药有限公司 sGC刺激剂
EA027909B1 (ru) 2012-11-30 2017-09-29 Астеллас Фарма Инк. Имидазопиридиновые соединения
US9776997B2 (en) 2013-06-04 2017-10-03 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-A]pyridines and their use
CN104327107A (zh) 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
US9796733B2 (en) * 2014-06-04 2017-10-24 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
EP3194386A2 (en) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2969265A1 (en) * 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines and their use
SI3507291T1 (sl) * 2016-09-02 2021-11-30 Cyclerion Therapeutics, Inc. Kondenzirani biciklični SGS stimulatorji
AU2019231724B2 (en) 2018-03-07 2024-06-27 Tisento Therapeutics Inc. Crystalline forms of an sGC stimulator

Also Published As

Publication number Publication date
PE20210124A1 (es) 2021-01-19
WO2019173551A8 (en) 2020-06-11
MA54638A (fr) 2021-11-10
KR102782810B1 (ko) 2025-03-14
WO2019173551A1 (en) 2019-09-12
AU2019231724A1 (en) 2020-10-08
JP7423539B2 (ja) 2024-01-29
KR20200128708A (ko) 2020-11-16
AU2019231724B2 (en) 2024-06-27
US20210115050A1 (en) 2021-04-22
MX2023004857A (es) 2023-11-24
CR20200458A (es) 2020-11-09
CL2021003536A1 (es) 2022-08-19
CL2021003530A1 (es) 2022-08-19
EP3762389B1 (en) 2024-02-28
TW201940487A (zh) 2019-10-16
MX2020009183A (es) 2020-10-08
MX2023004855A (es) 2023-11-24
US20250115611A1 (en) 2025-04-10
US11466015B2 (en) 2022-10-11
BR112020018212A2 (pt) 2020-12-29
SG11202008641WA (en) 2020-10-29
JP2021515015A (ja) 2021-06-17
EP3762389A1 (en) 2021-01-13
TWI823903B (zh) 2023-12-01
EA202092109A1 (ru) 2021-03-04
CL2021000301A1 (es) 2021-06-18
MX2023004858A (es) 2023-11-24
CA3092683A1 (en) 2019-09-12
CO2020012493A2 (es) 2020-10-30
US12122782B2 (en) 2024-10-22
CN111836812A (zh) 2020-10-27
CL2021003531A1 (es) 2022-08-19
IL276853B1 (en) 2026-01-01
IL276853A (en) 2020-10-29
ES2980256T3 (es) 2024-09-30
MX2023004856A (es) 2023-11-24
PH12020551394A1 (en) 2021-11-22
US20230095799A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
CO2020012493A2 (es) Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc)
CY1124612T1 (el) Συντηγμενοι δικυκλικοι sgc διεγερτες
PE20181802A1 (es) Derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridin-3-il)-6-oxo-6,7-dihidro-5h-pirrolo[2,3-d]pirimidina y los respectivos (1h-indazol-3-il) derivados como moduladores cgmp para el tratamiento de enfermedades cardiovasculares
UY39701A (es) 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek
PE20120121A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
MX376465B (es) Compuestos de pirazolo[1,5-4]piridina sustituidos como inhibidores de la quinasa ret.
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
CL2018002920A1 (es) Nuevos derivados de pirazolopirimidina
UY31493A1 (es) Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxilico
MX2020008237A (es) Inhibidores de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol de cgas para tratar enfermedades autoinflamatorias.
MX2021008145A (es) Polimorfo de macrociclo de diarilo.
SG10201907576SA (en) Salts of pi3k inhibitor and processes for their preparation
PE20171104A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2017001380A1 (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa
NZ748592A (en) Treatment for parkinson’s disease
UY30706A1 (es) Diaril, dipiridinil y arilpiridinil derivados y usos de los mismos
MX2022014858A (es) Formas solidas de pralsetinib.
UY37262A (es) [8-(fenilsulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il](1h-1,2,3-triazol-4-il)metanonas
EP4606433A8 (en) FORMULATIONS CONTAINING HETEROCYCLIC PROTEIN KINASE INHIBITORS
CL2013000434A1 (es) Compuestos derivados de 6,7-dihidro-3h-oxazolo(3,4) pirazina-5,8-diona, composicion farmaceutica que los comprende; proceso para prepararlos, y uso en el tratamiento de patologias mediadas por inhibicion de la emzima pde-5, como disfuncion erectil, litiasis, hiperplasia prostatica, disfuncion sexual femenia.
MX2020009185A (es) Proceso para la preparacion de estimuladores de guanilato ciclasa soluble.
MX2023008755A (es) Cristales de sal.
AR030241A1 (es) Compuestos derivados de tienopirrolidinona, su uso, medicamentos que los contienen, un procedimiento para preparar dichos compuestos y compuestos intermediarios
UY29532A1 (es) Derivados del ácido 6,7-dihidro-5h-imidazo(1,2-a)imidazol-3-sulfónico